Coya Therapeutics Inc. (COYA)
NASDAQ (CM) NASDAQ (CM) Primary 
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
On Tuesday, Coya Therapeutics, Inc. COYA released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial
Coya Therapeutics said on Tuesday its experimental Alzheimer's drug was safe and increased levels of a type of immune cells that help prevent neuroinflammation in patients with Alzheimer's disease enrolled in a small, mid-stage trial.
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
Coya Therapeutics is developing treatments for neurodegenerative diseases, with its lead drug COYA 302 showing promising early results in ALS trials. Despite recent delays, the adverse investor reaction presents an investment opportunity as the company progresses on its pipeline development. The partnership with Dr. Reddy's Labs validates COYA 302 and provides a mechanism for rapid commercial scaling upon FDA approval.
Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer
Coya Therapeutics is set to initiate a Phase 2 trial in ALS and release the topline results of a Phase 2 trial in Alzheimer's disease in the summer. The company's anti-inflammatory approach has received strong external validation. Recently, small open-label clinical trials in ALS and Alzheimer's have shown improvement or disease stabilization.
